

Special Issue

Advances in Rabies Vaccination

Message from the Guest Editors

Rabies remains one of the most lethal zoonotic diseases, causing an estimated 59,000 human deaths annually. Recent advancements in reverse genetics, structural vaccinology, mRNA vaccine platforms, and monoclonal antibody cocktails are reshaping our arsenal against the rabies virus and other lyssaviruses. Additionally, novel biologics for post-exposure prophylaxis, thermostable oral vaccines for wildlife reservoirs, and machine-learning-assisted risk assessment tools are extending protection to previously unreachable populations.

Our goal is to assemble **original research and reviews that together provide a comprehensive overview of current progress and future directions in rabies prevention and control.**

Research areas of interest include the following:

- **Immunological processes associated with rabies vaccines and correlates of protection;**
- **Rabies vaccine platforms**
- **Therapeutic monoclonal antibodies and passive immunization**
- **Thermostable and oral baits for wildlife and dog vaccination campaigns**
- **Studies on rabies transmission dynamics and vaccine coverage**
- **Optimization of post-exposure prophylaxis in resource-limited settings**
- **Innovative delivery systems**

Guest Editors

Dr. Ye Feng

Dr. Ming Zhou

Dr. Susan M. Moore

Deadline for manuscript submissions

31 August 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/253031

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).